Afamelanotide Legal Status: Approval, Research Use, and Regulatory Notes
FDA-approved (Scenesse) for erythropoietic protoporphyria (EPP) in adults. Also approved by EMA. Available only through restricted distribution programs (REMS). Prescription only.
Direct Answer
Afamelanotide (Scenesse) is FDA-approved for the prevention of phototoxicity in adults with erythropoietic protoporphyria (EPP) - a rare, severely debilitating condition. The Phase 3 evidence in EPP is solid and the approval is well-founded. Outside EPP, evidence for vitiligo is emerging in Phase 2. This is a legitimate, approved therapeutic for its specific indication.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Skin & Beauty
- Best for
- Erythropoietic protoporphyria (EPP) phototoxicity prevention, vitiligo (investigational), melanocortin research
Legal and Regulatory Status
FDA-approved (Scenesse) for erythropoietic protoporphyria (EPP) in adults. Also approved by EMA. Available only through restricted distribution programs (REMS). Prescription only.
Approval Stage
Afamelanotide is listed as FDA Approved. Approved uses, if any, are indication-specific and do not automatically apply to other claims.
Compliance Notes
- Regular skin and mole examinations recommended during treatment
- Not studied in patients with active melanoma or high melanoma risk
- Liver function should be monitored in EPP patients
- Use only for confirmed EPP diagnosis
Evidence Page
For the complete evidence review, see the main Afamelanotide guide linked below.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | EPP Phototoxicity Reduction (Level A), Skin Pigmentation (Level A), and Photoprotection (Level B) |
| Primary citation count | 3 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Afamelanotide Legal Status: Approval, Research Use, and Regulatory Notes." Last reviewed 2026-04-04. https://examinepeptides.com/answers/melanotan-i-legal-status/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.